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BACKGROUND: Stage IV colorectal cancer encompasses a broad patient population in which both curative and palliative management
strategies may be used. In a phase II study primarily designed to assess the efficacy of capecitabine and oxaliplatin, we were able to
prospectively examine the outcomes of patients with stage IV colorectal cancer according to the baseline resectability status.
METHODS: At enrolment, patients were stratified into three subgroups according to the resectability of liver disease and treatment
intent: palliative chemotherapy (subgroup A), conversion therapy (subgroup B) or neoadjuvant therapy (subgroup C). All patients
received chemotherapy with capecitabine 2000mgm
–2 on days 1–14 and oxaliplatin 130mgm
–2 on day 1 repeated every
3 weeks. Imaging was repeated every four cycles where feasible liver resection was undertaken after four or eight cycles of
chemotherapy.
RESULTS: Of 128 enrolled patients, 74, 22 and 32 were stratified into subgroups A, B and C, respectively. Attempt at curative liver
resection was undertaken in 10 (45%) patients in subgroup B and 19 (59%) in subgroup C. The median overall survival was 14.6, 24.5
and 52.9 months in subgroups A, B and C, respectively. For patients in subgroups B and C who underwent an attempt at curative
resection, 3-year progression-free survival was 10% in subgroup B and 37% for subgroup C.
CONCLUSIONS: This prospective study shows the wide variation in outcome according to baseline resectability status and highlights the
potential clinical value of a modified staging system to distinguish between these patient subgroups.
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The overall survival of patients with advanced colorectal cancer
has improved from a median of approximately 14 months achieved
with 5-FU/LV alone (Douillard et al, 2000; de Gramont et al, 2000)
to more than 19 months with the use of combination and
sequential cytotoxic therapies (Goldberg et al, 2004; Tournigand
et al, 2004; Souglakos et al, 2006). More recently, targeted
therapeutics have shown further incremental gains (Hurwitz
et al, 2004; Jonker et al, 2007; Van Cutsem et al, 2007) with the
prospect of extending survival beyond 24 months in the advanced
disease setting (Grothey et al, 2007). For the majority, treatment
remains of palliative benefit, with the possibility of cure restricted
only to those patients with disease suitable for surgical resection.
Before the advent of combination chemotherapy, the role of
metastectomy was limited to those patients who initially presented
with disease amenable to surgical resection. However, the high
tumour response rates achieved with modern chemotherapeutics
now enable a further proportion of patients with initially
inoperable disease to be converted to an operable status and
undergo liver resection with curative intent. Reports published by
Bismuth et al (1996) and Adam et al (2004a) have shown the
potential long-term survival achievable through the use of down-
sizing chemotherapy or ‘conversion therapy’ (Khatri et al, 2007)
and liver resection, with 5-year survival rates of 33% (Adam et al,
2004a).
Published data suggest that the ability to undertake liver
resection is a significant determinant of patient outcome in stage
IV colorectal cancer. However, this has never been formally
examined in a prospective study.
At the time of planning this study, one of the treatment options
for patients with inoperable metastatic disease isolated to the liver
was infused 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX)
(NICE, 2002). The combination of capecitabine and oxaliplatin
(CapOx) represented a convenient alternative regimen, with phase
II data available to support its use in the advanced disease setting
(Borner et al, 2002). During the course of the study, phase III data
showing the non-inferiority of CapOx compared with FOLFOX-4
have become available (Cassidy et al, 2008; Rothenberg et al, 2008).
The objectives of this study were to further assess the safety and
efficacy of capecitabine and oxaliplatin in the palliative disease
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ssetting and also in the peri-operative setting for patients with
potentially resectable liver disease. The study design enabled the
prospective evaluation of treatment outcomes according to the
baseline disease resectability status and provides a unique data set
in this patient population.
METHODS
This single-arm phase II study recruited patients referred to the
Gastrointestinal Cancer Unit at the Royal Marsden Hospital,
London and Sutton. The study was approved by the local Ethics
Committee and written informed consent was obtained from all
patients.
Patients
Eligible patients diagnosed with advanced colorectal cancer were
aged 18 years or older and had not received chemotherapy for
advanced disease. Other requirements included unidimensional
measurable disease, WHO (World Health Organisation) perfor-
mance status 0–2, adequate bone marrow function, adequate liver
function (bilirubin o1.5  ULN), calculated creatinine clearance
450mlsmin
–1 and life expectancy of 412 weeks. Patients were
excluded if they had clinically significant active cardiac disease
(congestive cardiac failure, coronary artery disease, cardiac
arrhythmia) or myocardial infarction within the last 12 months.
Previous adjuvant therapy was allowed, including the administra-
tion of oxaliplatin-containing regimens. Patients with significant
symptoms of peripheral neuropathy were excluded. Patients with
either resectable or non-resectable metastatic disease sites were
eligible for study enrolment.
Study design and treatment
For the purpose of outcome analysis, patients were stratified into
one of three subgroups according to their disease resectability
status. This was undertaken prospectively by the investigator at
the time of study enrolment as outlined in Figure 1. Stratification
was based on the considered feasibility of proceeding directly to
primary liver resection based on radiological findings, clinical
details and multi-disciplinary meeting (MDM) discussion. The
aim of stratification was to identify patient subgroups receiving
palliative chemotherapy (subgroup A), conversion therapy
(subgroup B) or neoadjuvant therapy (subgroup C). Stratification
was solely undertaken to allow the outcomes of each patient
subgroup to be evaluated independently and had no influence on
the care that patients received while participating in the study.
Pre-treatment CT imaging was undertaken within 28 days before
commencing study treatment. In addition, patients with liver-only
metastases underwent contrast-enhanced MRI imaging of the liver
and were discussed in a specialist hepatic MDM. Patients received
CapOx chemotherapy consisting of oxaliplatin 130mgm
–2on day
1 and capecitabine 1000mgm
–2 bd on days 1–14 repeated every
21 days. Patients aged 75 years or over received a reduced starting
dose (oxaliplatin 100mgm
–2and capecitabine 1500mgm
–2). Dose
reductions of oxaliplatin were instituted for grade X3 haemato-
logical toxicity (on day of treatment) and grade 3 peripheral
neuropathy or grade 2 neuropathy persisting between cycles.
Capecitabine dose reductions were instituted for non-haematolo-
gical capecitabine toxicities of Xgrade 2. Treatment was continued
for up to a total of eight cycles. In responding patients, further
cycles could be delivered at the discretion of the investigator. CT
(and MRI if liver-only metastases) response assessment was
undertaken after every four cycles. Patients considered to have
potentially resectable disease were re-discussed in the hepatic
MDM after every four cycles of treatment. The decision to use
surgery or RFA was based on the MDM discussion and was not
protocol specified. Liver resection was considered in cases in
which macroscopic clearance of disease with clear margins was
thought possible, while maintaining adequate residual liver tissue.
Surgical resections were planned on the basis of both CT and MRI
findings. The preferred timing for liver resection was after four
cycles of CapOx chemotherapy, with an interval of 3–6 weeks
between the end of chemotherapy and surgery recommended. In
cases in which disease remained inoperable, a further four cycles
of CapOx could be delivered before re-evaluation. Individual
liver lesions that showed a complete response to chemotherapy on
liver MRI (and intra-operative ultrasound where undertaken) were
not resected. In cases in which resection of both the primary
tumour and liver disease was necessary, this could be undertaken
as either a combined procedure or sequentially with four cycles of
CapOx delivered between each procedure. The use of long-course
pre-operative pelvic chemoradiotherapy was permitted in patients
with locally advanced rectal tumours. When used, this was
administered after an initial four cycles of CapOx chemotherapy.
Patients undergoing liver resection after four cycles of CapOx
received a further four cycles of post-operative chemotherapy.
After the completion of study therapy, patients were followed up
on at least a 3-monthly basis.
Statistical analysis
The primary outcome measure was radiological response rate after
four cycles of CapOx chemotherapy. A response rate of 50% was
considered acceptable and a response rate of 35% unacceptable.
Using a minimax design (Simon, 1989) and a one-sided a of 0.05, a
sample size of 117 allowed the exclusion of a radiological response
rate of less than 35% with 95% power. Planned recruitment was
130 patients to allow for 10% of patients being non-assessable.
Secondary outcome measures included progression-free survival
(PFS), overall survival (OS), proportion of patients undergoing
liver resection, chemotherapy-related toxicity and 60-day all-cause
mortality.
For all patients, progression-free survival was calculated from
the date of trial entry until disease progression, post-operative
recurrence or death from any cause. Overall survival was
Disease isolated to liver
+/– primary site.
Primary liver resection
not considered feasible 
*Stage IV disease
not isolated to the
liver 
Disease isolated to liver
+/– primary site.
Primary liver resection
considered feasible 
Subgroup A
Palliative therapy
Subgroup B
Conversion therapy 
Subgroup C
Neoadjuvant therapy
*Includes those patients with liver involvement and other metastatic disease sites potentially amenable to resection 
Figure 1 Prospective classification according to baseline resectability status. At the time of study entry, enrolled patients were classified into one of three
subgroups on the basis of the feasibility of undertaking primary liver resection.
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scalculated from the date of trial entry until death from any cause
or censored at last follow-up. Both PFS and OS were estimated
using the Kaplan–Meier method (Kaplan and Meier, 1958). The
objective response rate was assessed by CT according to RECIST
criteria (Therasse et al, 2000). Owing to a significant proportion
of patients undergoing liver resection after four cycles of CapOx,
radiological responses were not confirmed by repeat imaging.
Toxicities were evaluated and recorded using the National Cancer
Institute Common Toxicity Criteria version 2. A post hoc
univariate and step-up multivariate Cox regression analysis was
undertaken to examine for prognostic variables in all enrolled
patients and in the liver-only subgroups (B and C). Factors
included in the analysis for all patients were disease site (primary,
local, liver, peritoneal, nodal, bone, lung), number of metastatic
sites (1 vs 41), subgroup (A vs B vs C), age (o60 vs 460), PS (2 vs
0.1), disease-free interval (o12 vs 412 months), synchronous
presentation (Y vs N), CEA (o200 vs 4200), alk phos (o300 vs
4300), LDH (oULN vs 4ULN), WCC (o10 vs 410), Hb (411 vs
o11) and platelets (o400 vs 4400). For the analysis of liver-only
patients, largest metastasis (o5 vs 45cm) and number of liver
metastases (1 vs 41) were also included. PS and Alk phos were
excluded in the liver-only group because of low numbers. The data
set was locked and analysed in October 2009 with a median follow-
up of 60 months.
RESULTS
Patient characteristics
Between September 2002 and April 2006, a total of 128 patients
were recruited, with 74, 22 and 32 patients allocated to subgroups
A, B and C, respectively.
The primary reasons for patients to be considered for
conversion therapy (subgroup B n¼22) were large metastasis
(45cm) in five patients, multiple metastases (44) in 12 cases,
locally advanced primary in three patients and ill-placed lesions in
two patients.
The patient characteristics for each subgroup are shown in
Table 1. Patients in subgroup C were less likely to have presented
with synchronous metastatic disease and had a longer interval
between primary diagnosis and presentation with metastatic
disease. The median number of metastatic liver deposits was
lower in subgroup C compared with subgroup B, with a median of
2 (range 1–5) and 4 (range 1–15), respectively.
Toxicities
The commonest grade III/IV chemotherapy-related toxicities were
diarrhoea, neutropaenia and palmar plantar syndrome (Supple-
mentary Table 2). Oxaliplatin was discontinued early in four
patients because of peripheral neuropathy. Four patients discon-
tinued capecitabine because of cardiac chest pain; raltitrexed was
substituted for capecitabine in three of these cases. Two patients
suffered fatal pulmonary thrombo-embolic events while on
treatment. One patient suffered a fatal myocardial infarction and
another patient suffered a non-fatal myocardial infarction. One
death occurring during the first cycle of therapy was attributable
to diarrhoea and dehydration. No deaths were attributable to
neutropaenic sepsis, and 60-day all-cause mortality was 3.1%.
Radiological response and resection rate
The median number of cycles of chemotherapy delivered was
eight. Six patients (4.7%) were non-evaluable for response. By
intention to treat, the overall radiological response rate as assessed
by CT was 52.3% (95% CI: 43–61%); complete response 8.6%,
partial response 43.8%, stable disease 30.5% and progressive
disease 12.5%. The radiological response rate and liver resection
rate for each subgroup are summarised in Table 2. As would be
expected, a higher proportion of patients in subgroup C underwent
an attempt at liver resection than those in subgroup B. Two
patients in subgroup A underwent resection of pulmonary
metastases and another patient had pulmonary and liver
metastases resected. For patients undergoing an attempt at liver
resection, the median interval between the end of pre-operative
chemotherapy and surgery was 7.6 weeks (range 4–24 weeks).
Liver resections
A flow diagram indicating the treatment pathways of patients in
subgroups B and C is shown in Figure 2. One patient in group B
and two patients in group C achieved a complete response by liver
MRI. Liver resection was deferred in these patients. Radio-
frequency ablation (RFA) was used in a total of four patients.
Two patients in subgroup B received RFA: one in conjunction with
surgery and one as an alternative to surgery (liver resection was
abandoned as a result of peri-operative bleeding that occurred
while resecting the primary during a combined procedure). In
subgroup C, one patient declined surgical resection and opted
for RFA as an alternative. A further patient with significant
Table 1 Patient characteristics
All patients Subgroup A Subgroup B Subgroup C
Patient number 128 74 22 32
Median age (range) 62 (29–78) 61 (29–78) 68 (38–77) 59 (47–76)
Male (%) 77 (60) 44 (59) 12 (52) 21 (66)
PS 2 (%) 10 (8) 9 (12) 1 (4) 0 (0)
Primary in-situ at study entry 55% 41% 28%
Metachronous presentation of 412 months 27% 9% 44%
aSynchronous presentation 86% 53%
Median number of liver deposits (range) 4 (1–15) 2 (1–5)
aSynchronous presentation defined as the development of metastatic disease within 3 months of primary diagnosis.
Table 2 Patient outcomes
All patients n¼128 Subgroup A n¼74 Subgroup B n¼22 Subgroup C n¼32
Median number of cycles (range) 8 (1–12) 8 (1–8) 8 (1–12) 8 (1–8)
CT response rate CR/PR (%) 52% 47% 59% 59%
Attempt at curative resection (%) 32 (25) 3 (4) 10 (45) 19 (59)
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sco-morbidity received RFA as the risk of surgery was felt to be
high. A two-stage resection with portal vein embolisation was used
in two patients. One patient in subgroup C had both stages
performed successfully. In subgroup B, the patient developed
disease progression shortly after the first stage of the planned two-
stage resection. Macroscopic disease clearance was not achieved in
this case. Histopathological examination of resection specimens
revealed clear margins in 96% (eight out of nine in subgroup B and
all 19 in subgroup C) of cases. Pathological complete response was
found in two cases, one in each of subgroups B and C.
In subgroup C, a total of 23 patients (72%) achieved either liver
resection, RFA (with curative intent) or a complete radiological
response by MRI. In subgroup B, the corresponding figure is 11
patients (50%). There were no post-operative deaths related to
liver surgery.
Survival
At a median follow-up of 60 months, 100 (78.1%) patients have
died. One patient in subgroup A was not evaluable for PFS as they
received second-line irinotecan without documentation of pro-
gressive disease. The median overall survival for patients in
subgroups A, B and C was 14.6, 24.5 and 52.9 months, respectively.
Overall survival and progression-free survival outcomes for the
total patient population and for each of the subgroups are shown
in Table 3. Supplementary Figure 3 shows the Kaplan–Meier plot
for overall survival for all enrolled patients. Overall survival and
progression-free survival curves for each patient subgroup are
shown in Figure 3.
Of the 29 patients in subgroups B and C who underwent an
attempt at curative liver resection, six (20.7%) remain disease free,
† 1 patient changed from capecitabine to raltitrexed at cycle 2 due to chest pain.
*1 resection abandoned due to peri-operative bleeding, received RFA to solitary metastasis.
†1 patient changed from capecitabine to raltitrexed at cycle 2 due to chest pain.
*Includes patients who stopped oxaliplatin secondary to neuropathy.
one received capecitabine + mitomycin C.
one capecitabine + irinotecan. 
Commence CapOx
22 patients
†Completed
4 cycles CapOx
22
* Operated
8
Complete 4
post-op cycles
7 
1 inoperable at surgery
Completed
8 cycles CapOx
8
Operated
3
4 Inoperable
Complete response
1
2 PD
1 poor PS
1 lost to FU
Subgroup B
Subgroup C
2 PD
Commence CapOx
32 patients
†Completed
4 cycles neoadjuvant
CapOx
31
1 Death following
first cycle  
3 PD
2 RFA only
1 Death following
resection of primary 
Operated
19
*Complete 4
post-op cycles
15 
2 Inoperable at surgery
1 Completed 2 post-op cycles
1 No post chemotherapy
 
Completed
8 cycles neoadjuvant
CapOx
6
Operated
2
2 PD
Complete response
2
Figure 2 Flow diagram indicating the treatment pathway of patients in subgroups B and C.
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sall from subgroup C. Supplementary Figure 5 shows the
progression-free survival and overall survival for subgroup B
and C patients who attempted curative resection. The median
PFS for these patients with that attempt resection was 14.0 months
in subgroup B and 24.3 months in subgroup C. The corresponding
median overall survival was 31.3 months in subgroup B and 73.3
months in subgroup C.
DISCUSSION
Stage IV colorectal cancer encompasses a heterogeneous patient
population in which both palliative and curative treatment
strategies may be used. In this prospective study, we stratified
patients with stage IV disease into three subgroups according to
the feasibility of undertaking curative liver resection. All enrolled
patients received treatment according to a protocol-defined
strategy, with the planned delivery of eight cycles of CapOx
chemotherapy and liver resection considered after four or eight
cycles of treatment, where feasible. The comparative outcomes of
each subgroup were in keeping with our previous expectations.
Subgroup C had the highest proportion of patients attempting liver
resection, with 59% compared with 45 and 4% in subgroups B and
A, respectively. As would be expected, overall survival was also the
longest in subgroup C, with a median of 52.9 months compared
with 24.5 and 14.6 months for patients in subgroups B and A,
respectively. Examining the outcomes of only those patients who
underwent liver resection, we found that patients in subgroup C
continued to fare better than those in subgroup B. Seven (70%)
patients in subgroup B developed progressive or recurrent disease
within 12 months of surgery compared with only five (28.5%) in
subgroup C.
The stratification method adopted in this study was not based
on strictly defined criteria. Although this is a potential criticism,
we believe that the stratification method used is representative of
clinical practice in which factors such as the status of the primary
tumour may affect patient management. What is clearly demon-
strated by the results of this study is that even within the subgroup
of stage IV patients with liver-only metastases (subgroups B and
C), marked variation in patient outcome can be seen. The
difference in patient outcomes between subgroups B and C can
be understood in light of the differing disease characteristics
between subgroups (Table 1). Patients in subgroup B had more
numerous liver metastases and were also noted to have a shorter
median interval from primary diagnosis to the development
of metastases. The disparity in disease characteristics between
subgroups remained in those patients who underwent an attempt
at curative resection (Supplementary Table 5). These character-
istics are known adverse risk factors for disease recurrence
following hepatic resection (Schlag et al, 1990; Sato et al, 1998;
Fong et al, 1999; Iwatsuki et al, 1999; Tsai et al, 2007; Rees et al,
2008) and are likely to account for the inferior outcomes seen in
subgroup B. Data reported by Adam et al (2004a) has similarly
shown inferior survival outcomes for patients undergoing resec-
tion after conversion therapy, compared with those with disease
amenable to primary liver resection.
To further examine for potential baseline prognostic factors, an
exploratory univariate and multivariate Cox regression analysis was
undertaken (Supplementary Tables 6 and 7). For the entire patient
cohort, stratification to subgroup C, alk phos o300 and absence of
peritoneal disease were found to be independently predictive of both
PFS and OS. In the liver-only patient subgroup (B and C), no
independently significant prognostic factors for PFS were identified.
Stratification to subgroup B and age 460 years were noted to be
independently predictive of shorter overall survival.
In view of the wide variation in survival outcomes seen among
patients presenting with stage IV colorectal cancer, modification of
the AJCC staging system (Greene et al, 2002) to allow the sub-
categorization of stage IV patients has been proposed (Nagashima
et al, 2006; Poston et al, 2006, 2008; Nordlinger et al, 2007).
Currently, there remains no widely accepted method of sub-
classification; however, our data would lend support to the
suggested incorporation of liver resectability status in a revised
colorectal cancer-staging system (Nordlinger et al, 2007).
A strength of our study data is that the resectability status
of each patient was identified prospectively at study entry,
thus avoiding the potential pitfalls associated with retrospective
classification. The proportion of enrolled patients with liver only
disease was higher than would be expected at 42%. It is likely that
funding restrictions that applied to the use of oxaliplatin during
the period of the study (NICE, 2002) would have biased enrolment
towards patients with liver only disease and may have also resulted
in the underrepresentation of patients with operable metastases at
other visceral sites. This factor should not have influenced the
characteristics or the comparative outcomes of the individual
patient subgroups.
At the time of initiating this study, there were no data to support
the use of neoadjuvant chemotherapy in patients with resectable
liver metastases. The subsequently published results of the EORTC
40983 study now lend support to this approach (Nordlinger et al,
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Figure 3 Progression-free survival and overall survival by subgroup.
Table 3 Survival outcomes
All
patients
Subgroup
A
Subgroup
B
Subgroup
C
Patient number 128 74 22 32
Median PFS months 8.7 6.9 9.7 14.7
Median OS months 20.7 14.6 24.5 52.9
3-year OS
(95% CI)
32.4%
(24–41)
22.2%
(13–32)
23.8%
(9–43)
61.5%
(42–76)
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s2008). Although the 40983 study did not show a significant
progression-free survival benefit with peri-operative chemotherapy
on an intention to treat basis, an improvement in progression-
free survival of 9.2% at 3 years was seen in those patients who
achieved surgical resection. An additional noteworthy finding in
this study was an increase in the post-operative complication rate
in patients who received peri-operative chemotherapy at 25 vs 16%
in the surgery-alone arm (Nordlinger et al, 2008). Data suggest that
the choice of chemotherapeutic agents (Vauthey et al, 2006), length
of pre-operative therapy (Aloia et al, 2006; Karoui et al, 2006) and
interval between chemotherapy and surgery (Welsh et al, 2007)
may all influence the associated surgical morbidity. The relatively
short interval between chemotherapy and surgery in the EORTC
study (median 4.1 weeks) may have contributed to the excess
surgical complication rate seen.
Together with enabling cytoreduction, a further advantage of
pre-operative chemotherapy is in allowing for an assessment of
chemosensitivity, a marker of underlying disease biology (Charn-
sangavej et al, 2006). Progression on chemotherapy is an indicator
of poor outcome following hepatic resection (Adam et al, 2004b)
and may be used to aid the selection of appropriate surgical
candidates. In our study, the length of pre-operative chemotherapy
used in subgroup B was relatively short, with a median number of
four pre-operative treatment cycles. This is a shorter period of
pre-operative treatment than that used in other studies evaluating
conversion therapy (Bismuth et al, 1996; Alberts et al, 2005; Masi
et al, 2006) in which the duration of chemotherapy was typically
6 months. Our treatment policy of early resection may have
contributed to the relatively high rate of early post-operative
failure seen in subgroup B. In this high-risk group, a more
prolonged period of chemotherapy may have aided the selection of
a better prognosis patient group for resection by the exclusion of
those who progress while receiving chemotherapy.
Advances in surgery have significantly influenced this field of
practice with the criteria for disease resection becoming increas-
ingly broad (Poston et al, 2006; Nordlinger et al, 2007; Pawlik et al,
2008). Consequently it is now possible to undertake liver resection
in a greater proportion of patients with adverse disease features
who are at higher risk of early post-operative failure. A variety of
clinical prognostic scoring systems have been proposed (Fong
et al, 1999; Iwatsuki et al, 1999; Adam et al, 2004a; Malik et al,
2007; Arru et al, 2008; Kattan et al, 2008) to aid the identification
of patients at higher risk for disease recurrence and allow
treatment to be tailored accordingly. It is envisaged that advances
in molecular medicine will further identify reliable markers of
disease biology, thus enhancing our ability to predict both patient
outcome and individual treatment response (Charnsangavej et al,
2006; Neal et al, 2006; Pawlik and Choti, 2007; Amado et al, 2008).
The availability of robust methods to assess disease biology
will further enable a personalised approach to therapy, allowing
the rational application of both surgery and chemotherapy in an
individual patient and minimising the exposure to morbid
inventions.
CONCLUSION
The results of this prospective study illustrate the wide variation in
patient outcome according to baseline liver resectability status and
highlight the potential value a revised staging system may have in
clinical practice.
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